ataciguat (HMR1766) + placebo + cilostazol
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intermittent Claudication
Conditions
Intermittent Claudication
Trial Timeline
Feb 1, 2007 → Oct 1, 2008
NCT ID
NCT00443287About ataciguat (HMR1766) + placebo + cilostazol
ataciguat (HMR1766) + placebo + cilostazol is a phase 2 stage product being developed by Sanofi for Intermittent Claudication. The current trial status is completed. This product is registered under clinical trial identifier NCT00443287. Target conditions include Intermittent Claudication.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00443287 | Phase 2 | Completed |
Competing Products
12 competing products in Intermittent Claudication
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg | AstraZeneca | Approved | 85 |
| LLG783 + Placebo | Novartis | Phase 2 | 52 |
| Azithromycin plus chloroquine + sulfadoxine-pyrimethamine | Pfizer | Phase 3 | 76 |
| Ad2/HIF-1α/VP16 + Ad2/HIF-1α/VP16 + Ad2/HIF-1α/VP16 | Sanofi | Phase 2 | 51 |
| SL650472, Clopidogrel | Sanofi | Phase 2 | 51 |
| Givosiran | Alnylam Pharmaceuticals | Phase 1/2 | 38 |
| Givosiran + 5-probe cocktail | Alnylam Pharmaceuticals | Phase 1 | 30 |
| givosiran (ALN-AS1) + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Sapropterin Dihydrochloride | BioMarin Pharmaceutical | Phase 2 | 49 |
| Tetrahydrobiopterin 10 mg/kg + Tetrahydrobiopterin 20 mg/kg + L-Ascorbate + L-Arginine | BioMarin Pharmaceutical | Phase 1 | 30 |
| Placebo + 375 mg CK-2017357 + 500 mg CK-2017357 | Cytokinetics | Phase 2 | 49 |
| Pimavanserin 34 mg + Placebo | Acadia Pharmaceuticals | Phase 2 | 47 |